SCHEDULE: Yelin Lapidot Discloses 5.95% Stake in MediWound

Yelin Lapidot Holdings Management and its principals have disclosed a 5.95% beneficial ownership stake in MediWound Ltd. as of December 31, 2025.

Summary

• Yelin Lapidot Holdings Management Ltd., along with Dov Yelin and Yair Lapidot, reported beneficial ownership of 763,069 Ordinary Shares of MediWound Ltd.
• This represents 5.95% of MediWound's total Ordinary Shares outstanding, based on 12,821,433 shares as of December 31, 2025.
• The shares are held by mutual funds (328,985 shares, 2.57%) and provident funds (434,084 shares, 3.39%) managed by Yelin Lapidot's wholly-owned subsidiaries.
• The reporting persons disclaim beneficial ownership, stating the securities are held for the benefit of the fund members.
• The filing indicates the shares were not acquired or held for the purpose of changing or influencing control of MediWound.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive disclosure, as it indicates significant institutional interest in MediWound, which can be a vote of confidence, though it's a passive stake.

Positives

• A significant institutional investor, Yelin Lapidot, holds a substantial stake, potentially indicating confidence in MediWound's long-term prospects.
• The disclosure of a 5.95% stake by a reputable investment firm could attract further institutional interest in MediWound.

Risks

• The concentration of a significant portion of shares (5.95%) under one institutional umbrella could lead to potential volatility if Yelin Lapidot were to significantly alter its position.
• While the filing states the shares are not held for control, a large stake always carries the potential for influence on corporate decisions, even if passive.

Future Outlook

NA

Management Comments

• The securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.
• This Statement shall not be construed as an admission by Messrs. Yelin and Lapidot, Yelin Lapidot Holdings or the Subsidiaries that he or it is the beneficial owner of any of the securities covered by this Statement, and each of Messrs. Yelin and Lapidot, Yelin Lapidot Holdings, and the Subsidiaries disclaims beneficial ownership of any such securities.

Industry Context

StockSavvy.ai notes that institutional filings like this Schedule 13G provide transparency into significant ownership stakes, which can influence market perception and trading activity. For a biotechnology company like MediWound, a substantial institutional holding by an Israeli firm like Yelin Lapidot could signal confidence in its drug pipeline or market potential within the region or globally, potentially attracting other investors.

Comparison to Industry Standards

• A 5.95% stake is a notable position for an institutional investor in a publicly traded company, often placing them among the top shareholders.
• Compared to activist investors who might take similar or larger stakes (e.g., Carl Icahn's historical stakes in various companies, or Starboard Value's positions), Yelin Lapidot explicitly states this is not for control, aligning with typical passive institutional investment strategies.
• For biotech companies, institutional ownership is common, with many funds specializing in the sector. This level of ownership is consistent with a significant, but not controlling, passive investment.

Stakeholder Impact

• Shareholders: Increased transparency regarding a significant institutional holder. Could potentially lead to increased investor confidence or scrutiny.
• Management: Awareness of a large, passive institutional investor on the shareholder register.

Next Steps

• Yelin Lapidot Holdings Management Ltd. will continue to monitor its investment in MediWound Ltd.
• Future Schedule 13G/A filings will be made if there are material changes to their beneficial ownership.

Key Dates

Recommendation

The filing indicates a significant, passive institutional stake in MediWound by Yelin Lapidot. While this signals a vote of confidence from a major investor, the filing itself does not provide new operational or financial performance data to warrant a 'buy' or 'sell' recommendation. It primarily offers transparency on ownership structure. Therefore, a 'hold' recommendation is appropriate, advising investors to maintain their current position while monitoring future company performance and market developments.

Keywords

MediWound, Yelin Lapidot, Schedule 13G, Beneficial Ownership, Institutional Investor, MWND, Ordinary Shares, SEC Filing, Investment Management